Why Did STAAR Surgical (STAA) Stock Jump 20% After Hours?

STAAR Surgical (NASDAQ: STAA) surged 20% in after-hours trading after reporting Q1 2026 preliminary net sales of over $90 million, more than double the $42.6 million from the prior year. Growth was driven primarily by China and the Americas with double-digit expansion, while higher sales and cost streamlining are expected to boost adjusted EBITDA. However, the company faces headwinds in the Middle East, Europe, Africa, and Asia-Pacific due to geopolitical and macroeconomic pressures, and provided no forward guidance citing volatile global conditions.

04/09/2026, 3:35 AM • Benzinga

LENSAR Stock Plunges—Alcon Scraps Merger After Prolonged Regulatory Review

Alcon has terminated its merger agreement with LENSAR, a laser solutions company, after prolonged regulatory review by the Federal Trade Commission made the deal unattractive. The acquisition, originally agreed upon in March 2025 at $14.00 per share, faced extended delays and opposition. LENSAR shares plunged 25.44% in premarket trading to $7.65, hitting a new 52-week low.

03/17/2026, 9:04 AM • Benzinga

FDA Expands Approval For Staar Surgical's Popular Implantable Lens

The FDA approved an expanded age indication for Staar Surgical's EVO/EVO+ Visian Implantable Collamer Lenses, extending eligibility from ages 21-45 to 21-60 years old. This could add nearly 8 million refractive patients to the market. The approval is based on three-year clinical trial data showing strong safety profiles. Despite the positive news, the stock trades 9.8% below its 20-day moving average with bearish technical indicators, though RSI suggests oversold conditions.

02/18/2026, 5:18 AM • Benzinga

STAAR Surgical Stock Falls After Largest Shareholder Broadwood Gains Board Influence

STAAR Surgical shares declined as Broadwood Partners, which owns 31% of the company, gained board influence with two new directors joining alongside Christopher Wang of Yunqi Capital. The changes follow the failed merger with Alcon and include the departure of Chair Elizabeth Yeu, with CEO Stephen Farrell remaining until January 31, 2026. The stock is trading below key moving averages with mixed technical signals.

01/15/2026, 1:06 PM • Benzinga

LASIK Eye Surgery Market Size to Reach USD 3.77 Billion by 2033, Driven by Rising Vision Correction Demand – SNS Insider

The global LASIK eye surgery market is projected to grow from USD 2.25 billion in 2025 to USD 3.77 billion by 2033, at a CAGR of 6.68%. Growth is driven by rising refractive disorders, AI-enabled surgical innovations, and expanding healthcare infrastructure. However, concerns over long-term safety complications such as corneal thinning and dry eye are limiting adoption. Asia-Pacific is the fastest-growing region, while North America dominates with 44.26% market share.

01/14/2026, 10:00 AM • GlobeNewswire

Intraocular Lens Market Size to Reach USD 9.85 Billion by 2033, Growing at a CAGR of 6.48% - SNS Insider

The global intraocular lens market is projected to grow from USD 5.97 billion in 2025 to USD 9.85 billion by 2033, driven by rising cataract prevalence, aging populations, and advanced lens technologies. However, high costs of premium lenses and limited accessibility in developing regions remain key challenges. North America leads the market with 38.61% share, while Asia Pacific is expected to witness the fastest growth at 7.03% CAGR.

01/09/2026, 4:43 AM • GlobeNewswire

STAAR Surgical Merger With Alcon Fails After Shareholders Vote No

STAAR Surgical announced that shareholders did not approve its merger with Alcon Inc., which was valued at approximately $1.6 billion. The deal will be terminated with no termination fees owed by either party. STAAR will remain a standalone publicly traded company and focus on profitable growth and expanding its EVO ICL technology globally. Major shareholder Broadwood Partners (30.2% stake) and Yunqi Capital Limited (5.1% stake) had opposed the merger.

01/06/2026, 1:10 PM • Benzinga

STAAR Surgical's Top Investors Reject Sweetened Alcon Offer, Cite Flawed Sale Process

Top investors of STAAR Surgical, including Yunqi Capital and Broadwood Partners, have rejected Alcon's revised acquisition offer of $30.75 per share, citing a flawed sale process and insufficient valuation.

12/10/2025, 12:53 PM • Benzinga

SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates STAA, GES, SMLR on Behalf of Shareholders

Law firm Halper Sadeh LLC is investigating potential securities law violations and fiduciary duty breaches related to recent corporate sales involving STAAR Surgical, Guess?, and Semler Scientific.

10/11/2025, 10:54 AM • GlobeNewswire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates STAA and CYBR on Behalf of Shareholders

Halper Sadeh LLC is investigating potential securities law violations related to the mergers of Staar Surgical and CyberArk Software, encouraging shareholders to explore their legal rights and options.

09/29/2025, 2:39 PM • Benzinga

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates STAA and CYBR on Behalf of Shareholders

Law firm Halper Sadeh LLC is investigating potential securities law violations and fiduciary duty breaches for several companies, focusing on recent merger and acquisition transactions.

09/27/2025, 12:18 PM • GlobeNewswire

STAAR SHAREHOLDER ALERT: Kaskela Law LLC Investigates Fairness of Proposed STAAR Surgical Company (NASDAQ: STAA) Shareholder Buyout and Encourages Investors to Contact the Firm to Discuss their Legal Rights and Options

Law firm Kaskela Law LLC is investigating the fairness of STAAR Surgical Company's proposed buyout by Alcon at $28.00 per share, which is lower than the company's 52-week high of $38.60.

09/24/2025, 1:53 PM • GlobeNewswire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PGRE, ETNB, STAA on Behalf of Shareholders

Law firm Halper Sadeh LLC is investigating potential securities law violations and fiduciary duty breaches for several companies involved in recent merger and acquisition transactions.

09/20/2025, 8:49 AM • GlobeNewswire

STAA Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of STAAR Surgical Company is Fair to Shareholders

Halper Sadeh LLC is investigating the potential fairness of STAAR Surgical Company's sale to Alcon for $28.00 per share, examining whether the company's board adequately protected shareholder interests.

09/11/2025, 7:00 AM • GlobeNewswire

Alcon Cites Tariffs And Soft Market In Lowered Sales Outlook, Shares Fall

Alcon reported Q2 sales of $2.58 billion, missing estimates, and lowered its 2025 sales forecast to $10.3-$10.4 billion due to tariff impacts and soft market conditions. The company's stock dropped 8.58% following the announcement.

08/20/2025, 9:47 AM • Benzinga